Nanoform Finland Oyj (NANOFH) Earnings Call Transcript
November 19, 2026
Earnings Call Speaker Segments
Hello everyone, and a very warm welcome to the presentation of Nanoform's third quarter 2026 report. I'm Henri von Haartman, serving as your Director of Investor Relations. Presenting to you today will be our CEO Edward Hæggström, CFO Albert Hæggström, CCO Christian Jones, and CDO Peter Hänninen. You can watch this presentation as a webcast via investor call, and you also have the option to dial in and listen over the phone. The slides are displayed during the webcast, and you'll find them as well in the investor section of our webpage. Once the presentation wraps up, we'll take a Q&A, and questions can be submitted by calling in. Our agenda today begins with a brief introduction and the key highlights, followed by financials, and then we'll finish with commercial. With that, I'll hand things over to our CEO and founder, Edward Hæggström — please go ahead.
Henri, this is Edward, can you hear me?
Now I can hear you.
Hey, sorry about that—I ran into a technical glitch here. Welcome as well, on my behalf, and what you're seeing is the introduction to Nanoform. Just as a reminder, we provide two technology platforms... and we use these platforms to serve... unclear
Edward, this is Henri speaking. To everyone listening, Edward is joining us from London, and the line sounds pretty poor.
It's unclear how we're doing this... with the strategies and the season here, what we try to do is break the wall for both small molecules and large molecules.
Henri, maybe given the connectivity issues, perhaps Albert could jump in?
Yes, I think actually Edward lost connection there. Albert, are you there?
Yes. I can take —
Okay.
Glad you can hear me clearly. A brief overview of Nanoform. We hold proprietary technologies covering both the small molecule area and the large molecule area. We also possess distinctive expertise in formulation. As you'll recall, we began working with AI, STARmap, a great many years back, and the concept is that through AI we can identify which molecules are suitable for nanoforming. We serve many types of clients, global large companies, mid-sized firms, and biotechs. Our approach follows the standard industry business model, which means a mix of service fees, plus, as a technology provider, we also have development and commercial milestones. Regarding small molecules, we can provide commercial GMP supply, and beyond that, once products are launched, we expect royalties or profit shares as an added benefit—especially for our kernels. The mid-term business targets for 2030, which were introduced last December, call for three nanoformed medicines to be on the market by 2030, income growth averaging more than 50% annually from '26 through '30, and an EBIT margin exceeding 30% by 2030. Turning to GMP, we've now arrived there with the major news that we've found a way to bring the large molecule side up to GMP as well. In recent years, we've built a state-of-the-art GMP-certified facility for small molecules. We've got three manufacturing lines. The first one is already commercially licensed, provides multi-ton annual capacity, and lets us work with highly potent APIs. What's quite interesting is that we've also been able to scale up the CESS technology substantially and get very cost-efficient. Based on market intelligence, we now think that at commercial scale we're actually the cost leader compared with traditional spray-dried ASDs. Our lead small molecule product kernels are three: enzalutamide, apalutamide, and encorafenib — all nano-versions of those. Peter and Christian will cover those in more detail. We'll also discuss further details about the significant development from a few days back: our signing of the worldwide CDMO collaborator that allows our ultra-high concentrations for large molecules to move into GMP. Clients have asked for this quite often — when will GMP be available for biologics, for nanoformed biologics? We're delighted now that, working alongside this major partner, we aim to have GMP in place during the second half of next year. That agreement was executed a few days ago, and as a result the CDMO partner — a worldwide frontrunner in aseptic production of biologics and large molecules — will have a manufacturing line set up at its site in Germany. This is something we're genuinely enthusiastic about, since it gives Christian and his group a way to say to customers: look, you've already collaborated with us on the R&D side for biologics, and now, together with our partner at his facility in Germany, we can actually move you into the clinic. Turning to the financials, you can see the number of projects that were signed. Do bear in mind that during the summer months things generally slow down somewhat, both for signed projects and for revenue, because when you're away on holiday, no revenue gets booked. As you can see, in the third quarter we signed one additional non-GMP project compared with last year, which pushed the trailing 12 months to one more than the prior quarter. You're also seeing the proportion of GMP projects go up, and that's precisely what we set our sights on across the past year — we accept somewhat fewer high-risk efforts on the non-GMP side and put more emphasis on those where the odds are better that they'll progress into GMP. The picture has clearly changed as well: early on, a lot of test molecules came our way, and at this point, after clients have put us through our paces, we hold far more data and they understand our capabilities. These days they send us a greater number of live projects, so the chance those advance to GMP is greater. Turning to income, we saw robust revenue growth and total income kept climbing, while gross margin came in at nearly 90%, in line with what we target. Regarding operating expenses, as you can see, they have fallen considerably—35% lower across the first nine months. Indeed, the decline was even steeper in Q3, at 40% for the third quarter. EBITDA showed substantial improvement both over the first nine months and, in particular, during the third quarter. Keep in mind, as we look toward next year and consider how much revenue is required before we can move nearer to breaking even: during this year's first quarter, we were still operating at full tilt from the period when we were constructing the factory, and that level has since dropped considerably. On the cost side, comparisons will be simpler next year. Turning to our short-term business goals, those remain the same. We think there's a reasonable shot at keeping cash burn under €10 million. We intend to submit the initial marketing authorization application for a nanoformed medicine very soon, and that will be in the UK. If anyone wonders what "imminent" means, we're thinking in terms of weeks. Our goal this year is a larger number of signed non-GMP and GMP projects. At the nine-month mark, we were one ahead versus the prior year. A lot of effort is now going into the last one — securing development, licensing, and commercial supply agreements on multiple kernels before this year ends. Our business targets for 2030 remain the same. Like I said, we brought out three products, averaging 50% growth yearly over those five years, and through that approach we ought to reach an EBIT margin beyond 30%. With that said, Christian, over to you—go ahead.
Thanks, Albert. I'm glad to take you through what's new on the commercial side. First, a quick recap of the value we offer: we have two platforms that are proprietary. For small molecules, the aim is to make particles smaller and medicines better—nanometer-scale particles that can deliver genuine bioavailability gains, while also allowing tablets to be fewer and smaller and reducing the pill burden; it's straightforward, environmentally friendly, and scalable. The technology is also cost-competitive when set against spray-dried solid dispersions; right now, within our capacity at the Nanoform facility in Finland, we can scale up to 10 tons; we hold a clinical license and a GMP commercial license. For large molecules, the main emphasis is converting items now given intravenously into subcutaneous delivery. This is accomplished through nanoparticles down to 50 nanometers, ultra-high-concentration suspensions above 500 mg/mL, and stable formulations that may not require a cold chain while opening up new routes of administration. Our biologics technology does have additional uses, but that remains its primary application. Working with biotech and pharma clients and employing IP-protected technologies lets us bring more value to their products; we expect upfront fees, milestones, and royalties in return for the value we generate. We deliver considerably more value than a standard CDMO. Small is powerful, and our purpose here is making better medicines. Let me recap or walk through the commercial highlights for this quarter. The clear standout is the agreement we just signed with a global CDMO concerning our ultra-high-concentration large molecule technology, with targeted readiness for GMP supply for our first clients in the second half of 2027. For Nanoform, this is far and away an enabler. We've built up substantial R&D interest among clients across the US, Europe, and Asia regarding our technology; now we offer a critical pathway to GMP, which is in fact essential for striking commercial deals with these partners as well. Next, regarding our product kernels—I'll keep this brief since Peter will go into greater detail. Our first is Nanoenzalutamide, where we're pursuing a multi-track approach to regulatory submission across different agencies. As Albert noted, our initial market authorization application in the UK is nearly upon us, and we're in frequent dialogue with other regulators right now. Then there's Gliora, a project we've been developing that targets brain tumors. For this one, we're combining nano-APIs within a hydrogel formulation. We recently received very encouraging feedback from the FDA; that's excellent news, since it lowers the regulatory burden and boosts the program's attractiveness for partnering. One of our other clients, Plusvitech, is working on a molecule for lung cancer, and they have now enrolled their first patient in the Phase 1/2 clinical trial for repurposing aprepitant. That's great news. It really supports them as a business and will give confidence to move forward with a nanoformulation very soon. I also want to mention a recent publication with Takeda. There's nothing new in this information. We discussed it last year. This is work carried out with Takeda on respiratory drug delivery of alpha-1 antitrypsin. For Nanoform, it marks the first time our work has appeared with a major pharmaceutical company in a high-impact journal, and we're extremely proud of it, and we'll say more about it later. Overall, the number of regulatory engagements—including ones involving the FDA for both our small molecule and large molecule products—has increased considerably. Nanoform is very busy at the moment, and we're quite pleased with the commercial and regulatory momentum we're seeing. Let me share a bit about the Takeda work. What was involved there? Takeda, as you're aware, has a substantial plasma-based therapy area. In that area, alpha-1 antitrypsin is presently given to patients, with Aralast as the product, and it is administered intravenously. It's for lung disease. Typically a large portion of it, 98%, stays in the blood, with only a very, very small quantity actually getting to the lungs. The idea was whether we could deliver it through a dry powder inhaler by using nanoforming to create dry particles. We collaborated with them on an animal study. The outcome showed that 95% stayed in the lung, with only 5% reaching the blood. That result was extremely strong—they were thrilled, and we were delighted as well. Other methods can dry proteins and particles in this way, but spray drying may denature certain biologics. They tested spray drying too, but only a tiny fraction of the drug reached the lungs, unlike what nanoforming achieves. That was a really strong outcome. Then, if we look back a few weeks, we were at the PODD Conference, which is genuinely a key fixture on the drug delivery calendar. I would say the engagement there was truly at the C-level to SVP level, focused on business development and licensing in drug delivery. Nanoform gave a presentation and shared some of our data, but we were also the subject of a presentation by PharmaCircle. PharmaCircle is a business intelligence platform. Each year at PODD, they give a keynote address on the drug delivery landscape. Kurt Sedo of PharmaCircle was the presenter, and in that talk he concentrated on the IV-to-subcu area. Which technologies are leading? Halozyme and Alteogen are shown here as the ones pursuing the hyaluronidase route, while Nanoform's biologics platform comes in a close third. We felt very fortunate to have a central role at that event, which drew a crowd of more than 1,000 attendees. On the following slide, you'll see that our efforts continue along several fronts. We collaborate with our customers. We also spend time learning more about the best ways to deliver our products. Our background includes pre-filled syringes for biologics, and those work very well in practice. After that, we started looking into additional device possibilities. Midas and Gerresheimer visited our facilities in Finland and brought along the Gx InBeneO, one of their auto-injector devices. We were able to trial that device with our formulation, and it performed extremely well. Using a high-concentration suspension, we managed to deliver over a gram of mAb in under 15 seconds. We are genuinely enthusiastic about the possibility of combining ultra-high-concentration suspensions with devices too, which would allow higher drug dosages that otherwise wouldn't be achievable. At this point I'll pass things to Peter, who will take us to the next slide.
Thanks, Christian. First, I want to restate our expectation that the UK filing for nanoenzalutamide is imminent—and as Albert noted, that fits with our goal of submitting an initial marketing application for a nanoformed medicine before this year is out. Beyond that, we've kept up disciplined work on the remainder of the kernel pipeline and decided to deprioritize two early preclinical programs in it: an oral solid dosage form and the inhaled semaglutide project. The reason is simply that we see far more opportunities across the rest of the pipeline, and we want to direct our limited resources toward those programs. Among these other programs, we're now working to move both nanoapalutamide and nanoencorafenib into a pilot human study as the next step. As noted, we were extremely pleased with how the FDA responded to our development plan for Gliora. As a reminder, Gliora is a joint development with Revelio Therapeutics in which we combine nanoformed olaparib and temozolomide in a long-acting hydrogel given locally for high-grade gliomas. The goal is to boost efficacy and tolerability by delivering the drug steadily right into the tumor resection cavity. Feedback from a Type C meeting with the FDA, which in fact arrived ahead of schedule, backs the proposed CMC, preclinical, and clinical development strategy for this product. Importantly, I think, the FDA confirmed Gliora will be regulated as a standard drug-drug combination, with the polymer handled as an excipient. Overall, I believe this feedback will lower regulatory complexity and help our partnering and out-licensing discussions. Across both us and Revelio, plus a number of partners we're speaking with, everyone is extremely excited about this product. This is, of course, an area of high unmet need, and we believe it can be a truly terrific development program for us. We were also glad to hear from Plusvitech, in which we hold a 9% ownership share, that they have now enrolled the first patient in their clinical study evaluating aprepitant for a new indication. That ongoing study uses the commercial formulation available today, but in parallel—and this is our role—we are working with Plusvitech on a reformulation to greatly cut pill burden, since the current commercially available formulation would require these oncology patients to take several tens of capsules each day. Then, turning to biologics—obvious, of course, but I'll say it anyway—we see a large market taking shape in subcutaneous delivery of monoclonal antibodies, and we're very confident this will remain a continuing theme in the years ahead. There are three points on this slide. First, we believe subcutaneous delivery will become the dominant standard for new and marketed biologics. Then, to make that large-scale move from IV to subcu possible, suspension formulations matter a lot, since they allow high concentration levels, and that in turn translates into smaller injection volumes. Smaller injection volumes can help you sidestep the complicated formulations and devices you find with a number of the subcu products currently on the market for higher-dose antibodies. Since particle properties are so critical to how these perform, we have a lot of confidence, given what we have observed up to now, that our technology could become a technology of choice for enabling subcutaneous delivery through suspensions. Naturally, to make this happen, we have to reach the clinic. Right before summer, we announced that we had signed the first exclusivity deal for our technology, and that we intend to move it toward the clinic without delay. Now, with the news we put out this week, we have taken an important step toward that goal through the agreement we reached with the CDMO, and we can say confidently that we are aiming for GMP readiness in the second half of 2027. To wrap up on my end, there is an established market and business model for drug delivery technologies that can enable subcu delivery for biologics. This slide really shows why so many product developers in this space are actively seeking alternatives; for every target, there will always be some number of competitors who must find an alternative enabling technology because of the exclusivity deals that Halozyme and the others have been striking in this space; for ultra-high-concentration subcu delivery in particular, we are very confident that we have an opportunity here to be one of the first to reach clinic, to be first, and then to keep strengthening our position as a leader in this sector. I would point out that this was actually on one of the slides Christian spoke to, that every one of the other particle-based delivery technologies on the slide is labeled as preclinical. We very much look forward, at the next PODD, to perhaps having already changed that label when it comes to our platform. With that, I thank you and turn it over to Henri.
Thank you, Peter.
Morning, everyone, and thanks. Let me start with the CDMO and say congratulations on getting that agreement done. The strategic logic is pretty clear from where you sit, I think, but it might be interesting to turn it around: what do you believe the CDMO partner is really seeing, especially in the technology, and what did their side have to put in, I suppose through what was presumably a fairly extensive DD process, and how far did that perhaps bring in the US biotech company that is obviously potentially the target first molecule heading into the clinic? Thanks.
Christian and Peter, would either of you like to weigh in on what they see and on why they would want to sign a deal of this kind with us?
Thanks, Albert. I'm glad to start on that one, and then I'll pass things over to Christian. First, I believe they're seeing the same market dynamic that we see, which is that in the future the delivery of biologics won't be quite so dominated by IV formulations as it has been up to now, since IV has really been a necessity caused by the lack of technology choices available, rather than something preferred from a patient or treatment perspective. They see that change taking place, and they want a part of it. Only a limited number of technologies exist in that space, and I think we've now been working very, very closely with them on this for a good part of this year, with visits back and forth. I believe they see that we have a technology that is clever, scalable and robust, well-suited for clinical but ultimately commercial manufacturing, and that's the business they're in. I think that's where, ultimately, they want to serve clients and be paid for that service, and they see this as a great opportunity to build their own business. Maybe I'll turn it over to Christian for his thoughts.
Sure. Thank you, Peter. I would just like to say that they are clearly a big name in the biologics field. A substantial share of their operations and revenue will come from producing drug product in IV formulations. They also recognize that the market may be shifting and that a move toward more subcutaneous drug delivery is coming, and that this ultra-high-concentration area could well become a major part of what lies ahead, so they want a stake in it; they think Nanoform's technology may well turn out to be a true leader in that space. That is my response to that, Christian.
I'd also say that after we announced the deal with the US customer, a few folks asked us why any CDMO would want to let you install a line in their facility. Naturally, plenty of people hold plenty of views, and it's always hard to gauge before negotiations begin whether it will truly work. We've been quite pleasantly surprised that interest from various CDMOs in striking a deal with us to place our line in their facility has been very strong. As we mentioned in the last report, we had concrete offers from several reputable firms, and we've now selected the one where we felt the fit was truly perfect. All three parties — us, the CDMO, and the client as well — felt this is a very good fit. Their business model differs somewhat from ours. They think a great deal about the commercial stage, the end state. We like that, since it means the client can also see the path all the way through to commercial, not just development. Their model centers on fee-for-service, whereas ours leans more toward milestones and royalties over the long run, because at least at the outset we won't have GMP in our own facility; this was genuinely a win-win. When we were considering a year ago whether we could build it in Helsinki, our estimates were that it would cost 20, 30 million, roughly that, and it would take us 2 to 3 years if you're a bit conservative, and we lack deep knowledge or expertise in aseptic manufacturing. Now we have a partner with a very strong, long track record in aseptic manufacturing. Their facility is ready. We simply place our line there. The capex is a fraction of what it would have been had we pursued a greenfield build. Since our business models differ so much, that discussion was also, in a sense, surprisingly easy. I'd rate this fit between us, and also for the client, the customer, as making their timeline better. They can obtain GMP material, the batch for the clinic, far faster than they otherwise would. We are really, really positive about this recently signed agreement.
Thank you, that's clear. So I suppose the natural follow-up is about the potential license you have with your US client. What seemed to obviously trigger the move toward a more formal license was clearly tied to the kinds of capabilities around GMP. Could that potentially advance fairly soon simply because this agreement is now in place, or might it have to wait for that final confirmation of a fully functioning GMP line using your technology before it turns into a formal license? I'd just like a sense of that.
Let me begin, and then I'll let Peter carry on. I'll start by saying that one reason we also appreciate the partners we now have is that we believe they share our view that a speedy, high-quality process matters, since as everyone knows, being one year slow in the early stages of development, whether R&D or early clinical, can translate into a billion or several billions of lost revenue 10 years later. This is one of those situations where we genuinely like the partners we're working with here, because all of us share that sense of urgency that you can't afford to be slow just because it's early days; you need to keep the momentum at all times. I'd say we're confident that we can reach some form of final agreement sooner rather than later. Peter, would you like to add a little more?
My view is that our May statement remains valid, in the sense that they paid what might be described as a kind of reservation fee, in a sense, so as to allow time to gain line of sight to GMP manufacturing and entry into clinic with our technology. That is now in place. We expect matters to move forward from this point as we communicated earlier.
Thanks. Perhaps one last question, if I may, please, just regarding nanoenzalutamide—clearly it sounds as though a filing is imminent in the UK, so a rough estimate of the potential review timelines from there. And then just the status: you mention still doing some of the work on the Cmax side, so what are the potential timings around, I suppose, some conclusion of that work you're pursuing as well?
Sure. Let me begin by noting that, naturally, Nanoform isn't the party submitting the application—that's our partner or partners. We form part of that application through our contribution on the technology side. The timelines are the standard UK ones; you can look those up. As for how the different pathways differ, we were, naturally, encouraged by what came out of the advice meeting in August and the hybrid pathway. On the other areas, we're currently awaiting, shall we say, feedback from various countries—from the US FDA, from various countries in Europe—concerning the hybrid pathway following the shift in, so to speak, the regulatory landscape, if that's how you'd put it, or the new material that emerged; we'll share more with you over the coming months regarding the different areas, but right now our focus is on the fact that the timeline for submitting the UK application is imminent, which means we would meet our target of having the first one during 2026. Peter or Christian, is there anything you'd like to add?
Nothing on my end, no.
All right. Thanks. That's clear.
Hello, this is Christopher Uhde from SEB, and I appreciate you taking my question. I have just a single administrative question, if I may. Could you explain how you've been recognizing revenue from the retainer fee tied to the US biotech, and at what point do you anticipate it will be fully recognized? Thank you.
Certainly; as we mentioned before, recognition happens across a 12-month span covering a one-year period, and it's linear — you take the $1 million, convert it into euros, divide that by 12, which gives you the monthly figure, and then multiply by three to arrive at the third quarter portion. That pattern will keep going until 12 months have passed since the signatures were made.
All right. Thanks.
Hello, I’ve got a few questions, beginning with the CDMO deal. First, what’s the right way to think about operating expenses after this deal? My assumption is that you’ll need to, say, move some staff over to Germany.
Some of our staff will travel there when the line is tech transferred and brought into operation jointly with the CDMO personnel, but after it is running, we won’t keep permanent staff there. It will fall under the CDMO’s responsibility, supervision, and QMS system; we won’t have permanent staff in Germany.
All right. Could you give us a bit more detail on the commercial arrangement that exists between your company and the CDMO? Is there going to be any up-front payment from your side? Are retainers part of this? And in the end, what share of royalties would they receive?
What I've been attempting to convey is that the two business models differ considerably: ours centers on milestones as well as royalties over the longer term, while theirs is the classic CDMO model built on fee-for-service. Every project begins at Nanoform, where we carry out our usual POCs and POPs along with tech transfers, and once it moves to the CDMO, that partner naturally holds a contract with the end clients, who then pay them for clinical batches, vials, or whatever is required. As for the contract, or agreement, that we and the CDMO have in place, no details will be disclosed.
All right. Last thing from me on the CDMO deal: how should we frame the revenue tied to the existing agreement with the US biotech company? In what way might those revenues build up and move forward now that the GMP manufacturing issue has been resolved?
When we put out the press release, what we stated was that naturally we hold an exclusivity arrangement, or agreement, with the end customer, and that's the business model on our side: we bring customers on under exclusivity agreements, and that sits apart from whatever other agreements exist with the CDMO and so forth. What we said at that point was that the overall potential milestones might reach high tens of millions across the whole period, covering development milestones, regulatory milestones and sales milestones, along with a low to mid-single-digit tiered royalty.
All right, and then moving along, I'm just curious about the overall commercial momentum that you're seeing right now. Do you see opportunities for additional deals with, let's say, listed customers tied to small and large molecules over the coming six months?
Christian, would you like to handle this question? How do you view the commercial momentum?
Absolutely, and thank you, Sami. Yes, momentum does seem to be building, especially where biologics are concerned, though the small molecule area shows it too. Over the coming six months, I'd be quite hopeful that we complete additional deals similar to those we've discussed today.
All right. And then last of all, I believe you mentioned that progress toward cash flow break-even will be made over the coming year. I just wanted to verify: did you really mean that a break-even point could be reached at some stage next year, or was the thought that further progress would be made during next year?
Of course, we'll come out with targets for next year at the time of our next report, the full year, but what I was saying is that we will keep making progress toward that. I didn't say we would reach it next year, but the official target will come when we report the full-year numbers.
Thank you. That's all I wanted to ask.
Edward, can you hear me?
Yes, I am connected.
Would you like to offer a few remarks?
I'm genuinely very pleased. To start, I want to apologize that I couldn't join in person. Apparently the connectivity here in London isn't great. What you've witnessed is how deep our bench is. Even with me sitting in the listener's seat, the management team members were capable of carrying the conference. I believe that's something worth noting. Next, I'd like to remind everyone, based on the first slides, that we now have 2 tech platforms that will soon reach GMP level. That means 2 S-curves to ride. It's also worth remembering that we currently have a small molecule facility getting ready to launch Nano-Enza. Internally, we'll be launch-ready next year, and at the end of next year we'll also begin producing nanoformed material for the commercial launch; that's one key milestone on a long journey. Today we've discussed the large molecules a great deal, and that is, of course, perhaps the top news this week; it's very important to grasp that the small molecule leg and the large molecule leg are now becoming equally strong, and strong they are; the growing interaction with regulatory bodies globally was also mentioned. This is something we'll be talking about more and more, because it will have a big impact on what we do. On my behalf, many thanks, and I apologize for the unclear audio.
Thanks, Edward, for that. On behalf of Nanoform, I'd like to thank everyone for joining us today. Should you have any further questions, please do get in touch with us. We wish all of you a wonderful Thursday afternoon and evening. Thanks, and goodbye.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nanoform Finland Oyj transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Nanoform Finland Oyj earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.